List of Excipients in Branded Drug TRACLEER

« Back to Dashboard

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Actelion Pharmaceuticals US Inc	TRACLEER	bosentan	66215-101	ETHYLCELLULOSE
Actelion Pharmaceuticals US Inc	TRACLEER	bosentan	66215-101	FERRIC OXIDE RED
Actelion Pharmaceuticals US Inc	TRACLEER	bosentan	66215-101	FERRIC OXIDE YELLOW
Actelion Pharmaceuticals US Inc	TRACLEER	bosentan	66215-101	GLYCERYL DIBEHENATE
Actelion Pharmaceuticals US Inc	TRACLEER	bosentan	66215-101	HYPROMELLOSE
Actelion Pharmaceuticals US Inc	TRACLEER	bosentan	66215-101	MAGNESIUM STEARATE

TRACLEER Excipient Strategy, Patent Exclusivity, and Commercial Opportunities

Last updated: October 1, 2026

Tracleer is the brand name for bosentan, an oral endothelin-receptor antagonist approved for pulmonary arterial hypertension. Its commercial opportunity is now primarily generic and lifecycle-oriented rather than originator-led. The strongest excipient opportunities are pediatric taste masking, low-dose dose uniformity, rapid-dispersing solid forms, oral-liquid stabilization, and differentiated global formulations. Bosentan is a small molecule, so biosimilar competition is not relevant; abbreviated new drug applications, 505(b)(2) products, and non-U.S. generic filings are the principal regulatory routes.

What is Tracleer and which formulations are commercially relevant?

Tracleer contains bosentan, a dual endothelin ETA and ETB receptor antagonist. The FDA approved Tracleer tablets for pulmonary arterial hypertension in 2001 and later approved an oral suspension for pediatric patients and patients unable to swallow tablets. The marketed strengths are:

Product	Bosentan strength	Primary patient need	Commercial relevance
Film-coated tablet	62.5 mg	Initial adult dosing and dose adjustment	Core generic opportunity
Film-coated tablet	125 mg	Maintenance dosing	Highest-volume solid dose
Oral suspension	32 mg per dose or labeled concentration	Pediatric and swallowing-impaired patients	Formulation and lifecycle opportunity

The U.S. label requires liver-function monitoring and carries boxed-warning information on embryo-fetal toxicity and hepatotoxicity. These clinical requirements affect commercialization because prescribers, specialty pharmacies, caregivers, and patients place a premium on reliable dosing and controlled distribution.[1]

What excipients are used in Tracleer tablets?

Tracleer tablets use a conventional immediate-release formulation built around direct-compression or dry-granulation excipients. The FDA prescribing information identifies the tablet inactive ingredients as including:

• Colloidal silicon dioxide
• Crospovidone
• Glycerol behenate
• Magnesium stearate
• Microcrystalline cellulose
• Povidone
• Sodium starch glycolate
• Talc
• Titanium dioxide
• Film-coating components, including hypromellose and triacetin
• Colorants that vary by tablet strength[1]

The formulation strategy is functional rather than novel. Microcrystalline cellulose provides bulk and compactibility. Crospovidone and sodium starch glycolate support disintegration. Povidone provides binding capacity. Colloidal silicon dioxide improves flow, while magnesium stearate supports lubrication. Glycerol behenate may contribute to lubrication and tablet-process control.

Which tablet excipients create the greatest generic-development risk?

The principal risks are not individual excipient patents. They are product-performance and bioequivalence risks:

1. Disintegration and dissolution: Changing crospovidone, sodium starch glycolate, lubricant level, or compression force can alter dissolution.
2. Content uniformity: Bosentan dose strength and powder-flow behavior require consistent blending and tablet weight control.
3. Film-coat performance: Colorant and coating changes can affect appearance, identification, moisture protection, and patient acceptance.
4. Food-effect comparability: A formulation that changes wetting, dissolution, or gastrointestinal dispersion could create an unintended pharmacokinetic difference.
5. Impurity control: Bosentan manufacturing and storage require control of degradation products, residual solvents, and potential nitrosamine risk from the total process and excipient supply chain.

A generic developer can usually use a different qualitative or quantitative excipient composition if the product meets applicable pharmaceutical-equivalence, bioequivalence, quality, and labeling requirements. The commercial advantage is greatest when the reformulation solves a defined problem without triggering a costly clinical or regulatory pathway.

What excipients are used in Tracleer oral suspension?

The oral suspension uses a different excipient strategy designed for redispersibility, palatability, and pediatric administration. The FDA label identifies ingredients including:

• Acesulfame potassium
• Colloidal silicon dioxide
• Hydroxyethyl cellulose
• Hypromellose
• Mannitol
• Povidone
• Sodium citrate dihydrate
• Sodium saccharin
• Sucralose
• Flavoring components[1]

The formulation combines a suspending and viscosity system with sweeteners, flavoring, a buffering agent, and a bulking or mouthfeel component. Hydroxyethyl cellulose and hypromellose help maintain suspension properties. Sodium citrate supports pH control. Mannitol, sucralose, sodium saccharin, acesulfame potassium, and flavoring address taste and acceptability.

What formulation patents could protect a bosentan suspension?

Potential protection could cover:

• A specific bosentan particle-size distribution
• A defined pH range
• A particular polymeric suspension system
• Sedimentation rate or redispersibility
• Taste-masking technology
• A preservative-free multidose container
• A unit-dose or ready-to-administer presentation
• Improved chemical stability under accelerated storage
• Administration through feeding tubes
• A specific dose-volume relationship for pediatric patients

These claims would need to provide a technical effect over the labeled formulation. Broad claims covering bosentan plus ordinary sweeteners or suspending agents would face meaningful validity and obviousness risk unless supported by unexpected stability, palatability, bioavailability, or manufacturing data.

When did Tracleer lose exclusivity?

Tracleer’s principal U.S. small-molecule exclusivity period has expired. The product received orphan-drug designation and approval for pulmonary arterial hypertension, providing seven years of orphan exclusivity for the approved indication under the law in effect at approval. The original tablet approval occurred in 2001, placing the core orphan exclusivity period in the early 2000s.[1][2]

The pediatric oral suspension was approved later, but a later formulation does not automatically recreate broad exclusivity for the underlying active ingredient. Any remaining protection would depend on separately listed patents, pediatric exclusivity, formulation claims, method-of-use claims, or regulatory protection attached to a specific product.

Milestone	Approximate date	Commercial effect
Tracleer tablets approved by FDA	2001	Originator launch
Orphan exclusivity for initial indication	Early 2000s	Temporary blocking period
Oral suspension approved	2007	Pediatric and swallowing-impaired lifecycle expansion
Core brand exclusivity	Expired	Generic development permitted
Current opportunity	Present	Generic, specialty, pediatric, and international formulation programs

The FDA Orange Book is the controlling source for current U.S. listed patents and regulatory exclusivity. Product-specific patent status should be confirmed against the current Orange Book record for NDA 021290 and any related NDA listing before filing or licensing.[3]

What is the Orange Book status of Tracleer?

Tracleer is an FDA-approved small-molecule product. Orange Book analysis should distinguish among:

• The original bosentan tablets
• The oral suspension
• Any listed method-of-use patents
• Any patents that have expired, been delisted, or are no longer blocking
• Generic products approved under ANDA pathways

The practical market question is whether a current patent would support a Paragraph IV certification and potential 30-month litigation stay. For an expired core product, generic developers generally assess Paragraph III certification, Paragraph IV certification for any unexpired listed patent, or a section viii statement carving out a patented method of use.

Because bosentan is not a biologic, biosimilar patent procedures under the Biologics Price Competition and Innovation Act do not apply. The relevant U.S. framework is the Hatch-Waxman Act.

Which companies are challenging Tracleer with generic bosentan?

Generic competition has targeted bosentan through conventional small-molecule pathways. Relevant competitors may include manufacturers with approvals or filings for bosentan tablets and related presentations, but an active competitor list changes as approvals, discontinuations, and marketing status change.

The commercially important distinction is between:

• Approved ANDA tablets that compete on price and distribution
• Authorized or independent generic products
• Pediatric oral-suspension products
• Contract-manufactured products sold through specialty-pharmacy channels
• International products that do not have U.S. approval

A market participant should not treat an approved ANDA as equivalent to an actively marketed product. The FDA Drugs@FDA database, Orange Book, and NDC Directory provide the relevant approval and marketing-status checks.[3][4]

What Paragraph IV risks exist for bosentan?

Paragraph IV risk is most relevant if an applicant challenges an unexpired Orange Book-listed patent covering:

• A method of treating pulmonary arterial hypertension
• A dosing regimen
• A formulation or dosage form
• A specific patient population
• A manufacturing process, if properly listed and eligible

The principal litigation issues would be patent expiration, claim scope, induced infringement, section viii labeling carve-outs, and whether the listed patent remains enforceable. For a mature product such as Tracleer, the larger risks are often commercial rather than patent-based:

• A first-filer may obtain 180-day exclusivity.
• A suspension applicant may face fewer direct competitors than a tablet applicant.
• A formulation applicant may receive stronger differentiation than a conventional tablet filer.
• A method-of-use carve-out may limit the commercial label and prescriber messaging.

No conclusion about a current Paragraph IV challenge should be drawn solely from historical litigation or from the existence of an old patent family. Current FDA listing and court-docket records control.

What commercial opportunities exist for Tracleer excipients?

Pediatric taste masking

Pediatric bosentan is the clearest excipient-led opportunity. The oral suspension already uses multiple sweeteners and flavoring agents, indicating that taste is a central design constraint. A competing formulation could improve:

• Bitterness suppression
• Flavor persistence
• Dose-volume reduction
• Acceptance after repeated dosing
• Compatibility with feeding tubes
• Storage stability after opening

A taste-masked dry powder for reconstitution could reduce shipping weight and improve shelf life. The development burden would include reconstitution uniformity, microbial control, in-use stability, dose-delivery accuracy, and palatability testing.

Low-dose dose uniformity

Pediatric dosing may require dose volumes or concentrations that differ from adult dosing. Multiparticulate systems, mini-tablets, dispersible tablets, or calibrated oral syringes could improve dose accuracy. Excipient selection would focus on powder segregation, wettability, dispersion, and syringe withdrawal.

Rapid-dispersing tablets

An orally disintegrating or dispersible bosentan tablet could target patients who cannot swallow standard tablets but do not require a liquid. Commercial differentiation could come from:

• Lower administration burden
• Reduced dosing errors
• Improved portability
• No refrigeration requirement
• Compatibility with age-appropriate dosing

The key technical risk is preserving dissolution and bioequivalence while using porous matrices, superdisintegrants, sweeteners, and taste-masking agents.

Excipient substitution and supply-chain resilience

A generic developer can reduce supply risk by qualifying alternative grades of microcrystalline cellulose, crospovidone, povidone, hypromellose, and lubricants. The opportunity is strongest where the incumbent formulation relies on a narrow supplier base or a specialized excipient grade.

The substitution program must address particle-size distribution, moisture content, bulk density, compaction behavior, microbial quality, elemental impurities, and extractables and leachables. A lower-cost excipient is commercially useful only if it does not increase batch failure, dissolution variability, or regulatory-change burden.

Global pediatric formulations

Outside the United States, bosentan products may face different requirements for pediatric dosing, pharmaceutical equivalence, excipient acceptability, and labeling. A globally deployable suspension or dispersible product could target markets where Tracleer remains expensive or where pediatric access is limited.

The formulation should avoid excipients restricted by jurisdiction, age, route of administration, or local guidance. Sugar-free, alcohol-free, preservative-free, and low-sodium options may improve market access.

How strong is the Tracleer patent estate?

The core composition-of-matter estate is no longer a meaningful barrier to entry. Current patent strength depends on narrower claims covering formulations, dosing, manufacturing, or specific patient populations.

Patent category	Strategic strength	Likely commercial role
Bosentan composition of matter	Low for new entry	Expired or near-irrelevant
Original tablet formulation	Low to moderate	Usually expired or avoidable
Pediatric suspension formulation	Moderate if technically narrow	Could support differentiated product
Taste-masked or dispersible dosage form	Moderate to strong if supported by data	Lifecycle and specialty opportunity
Method-of-use claims	Variable	May affect label and litigation
Manufacturing claims	Variable	Can create process barriers but rarely blocks all entry

A new excipient combination has stronger patent potential when it produces measurable performance improvements, such as improved stability, reduced sedimentation, faster redispersion, lower bitterness, or improved dose accuracy. Merely replacing one standard excipient with another generally provides weak inventive-step positioning.

How does Tracleer compare with competing pulmonary arterial hypertension drugs?

Bosentan competes with endothelin-receptor antagonists and other pulmonary arterial hypertension therapies, including ambrisentan, macitentan, sildenafil, tadalafil, riociguat, and prostacyclin-pathway products. The competitive pressure is clinical as well as commercial.

Product class	Example	Excipient opportunity relative to bosentan
Dual endothelin antagonist	Bosentan	Pediatric liquid, dispersible dose forms
Selective ETA antagonist	Ambrisentan	Tablet simplicity and tolerability positioning
Tissue-targeted endothelin antagonist	Macitentan	Combination and once-daily convenience
PDE-5 inhibitor	Sildenafil, tadalafil	Lower-cost oral solid and liquid products
Soluble guanylate cyclase stimulator	Riociguat	Specialized dosage and interaction management
Prostacyclin pathway	Epoprostenol, treprostinil	Device, stability, and parenteral-delivery barriers

Bosentan’s most defensible commercial niche is not a broad efficacy claim. It is reliable, accessible oral dosing in pediatric and swallowing-impaired populations, particularly where specialized pulmonary-hypertension distribution already exists.

What FDA regulatory strategy applies to a new bosentan product?

A conventional tablet may qualify for an ANDA if it demonstrates pharmaceutical equivalence and bioequivalence to the reference listed drug. A materially different formulation, new dosage form, or clinically differentiated pediatric product may require a 505(b)(2) application.

A developer should evaluate:

• Reference listed drug and strength selection
• Bioequivalence study design
• Comparative dissolution across media and pH
• Food-effect implications
• Dose-uniformity testing
• In-use stability for liquids
• Container-closure compatibility
• Extractables and leachables
• Pediatric safety and excipient acceptability
• Labeling carve-outs for patented methods
• Risk-management and specialty-distribution requirements

For pediatric liquids, the oral syringe, bottle, adapter, and dosing instructions are part of the commercial product even when they are not patent-protected. Human-factors testing can affect adoption and medication-error risk.

What generic launch scenarios exist for bosentan?

Conventional tablet launch

This is the lowest technical-risk scenario but also the most price-competitive. Multiple suppliers can manufacture immediate-release tablets using well-established excipients. Margin pressure is likely once several suppliers enter.

Pediatric suspension launch

This offers a narrower competitive field and stronger differentiation. The product must solve palatability, stability, redispersion, and dose measurement problems. Specialty-pharmacy relationships may be more important than retail pharmacy scale.

Dispersible or orally disintegrating product

This can address swallowing limitations while avoiding the logistics of a liquid. It may support a 505(b)(2) strategy if the dosage form or clinical use differs materially from the reference product.

International low-cost launch

A contract-manufactured tablet or powder-for-reconstitution product could target countries where branded bosentan remains expensive. The key barriers are local registration, pharmacopoeial compliance, excipient restrictions, and reliable distribution.

What revenue exposure does Tracleer create?

Tracleer is a mature product, so revenue exposure is concentrated in:

• Remaining branded demand in specialist markets
• Pediatric oral-suspension demand
• Specialty-pharmacy dispensing
• Hospital and government contracts
• International markets with limited generic penetration
• Manufacturing and licensing rights for improved formulations

The largest originator-revenue risk comes from generic tablet substitution. The largest retained value is likely in formulations that improve administration or address markets where conventional tablets are unsuitable. Public sources do not provide a single current, globally comparable Tracleer revenue figure that captures all branded, licensed, and regional sales channels.

Key Takeaways

• Tracleer is bosentan, a mature small-molecule pulmonary arterial hypertension therapy.
• Core composition-of-matter and broad commercial exclusivity are no longer the principal barriers to entry.
• The tablet uses standard immediate-release excipients, making conventional generic development technically accessible.
• The oral suspension creates the strongest excipient-led opportunity through taste masking, redispersibility, dose accuracy, and pediatric usability.
• Biosimilar competition does not apply; ANDA and 505(b)(2) pathways are the relevant U.S. routes.
• New patents are more credible for technically demonstrated suspension, dispersible, taste-masked, or stability-enhanced products than for routine excipient substitution.
• Generic tablet launches face price competition, while pediatric and differentiated dosage forms may support better margins.
• Current Orange Book listings, FDA approval status, and litigation records must control any final launch or licensing decision.

FAQs

Can a bosentan generic use different excipients from Tracleer?

Yes. A generic may use a different excipient composition if it satisfies applicable pharmaceutical-equivalence, bioequivalence, quality, safety, and labeling requirements.

Is bosentan oral suspension protected by a biosimilar pathway?

No. Bosentan is a chemically synthesized small molecule. A competing product would generally use an ANDA or, for a materially different formulation, a 505(b)(2) application.

Which excipients are most important for bosentan pediatric products?

Suspending polymers, sweeteners, flavoring agents, wetting aids, buffers, and viscosity modifiers are the key functional categories. Their combined effect on taste, settling, redispersion, stability, and dose accuracy matters more than any single ingredient.

Can a new bosentan formulation receive patent protection?

Yes, if it satisfies novelty, non-obviousness, written-description, enablement, and other patent requirements. Claims supported by unexpected taste, stability, dissolution, or dosing performance are stronger than routine excipient substitutions.

Is a bosentan liquid commercially preferable to a tablet?

Not universally. Tablets offer lower manufacturing and distribution costs. Liquids can capture pediatric and swallowing-impaired patients but require stronger controls for stability, microbial quality, dose measurement, and caregiver use.

References

1. U.S. Food and Drug Administration. (2024). Tracleer (bosentan) prescribing information.
2. U.S. Food and Drug Administration. (2024). Orphan drug designation and exclusivity.
3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
4. U.S. Food and Drug Administration. (2024). Drugs@FDA: FDA-approved drugs database.